Coach vs. cancer in BMS-backed awareness effort

Share this article:
Coach vs. cancer in BMS-backed awareness effort
Coach vs. cancer in BMS-backed awareness effort
Former Steelers coach Bill Cowher is fronting a Bristol-Myers Squibb-backed "Melanoma Exposed: Screen. Protect. Know. Tell" awareness campaign.

The campaign will offer free public skin screenings at Giants, Dolphins, Broncos and Ravens games. It's aimed at men in particular, since nearly twice as many men die from the cancer each year as do women. Cowher, whose wife died of melanoma in 2010, told ESPN: "Men are naive to their bodies," Cowher said. "They don't pay attention to their skin like women do."

The launch of the campaign by BMS and a host of patient advocacy groups was keyed to the release of a survey showing widespread ignorance among Americans about the disease. Researchers found that only 10% of Americans were concerned about the disease, with which 70,000 are diagnosed annually, and more than half don't know that multiple moles are a risk factor for melanoma. Two-thirds say they don't conduct skin self-examinations.

The campaign website, MelanomaExposed.com, encourages visitors to “Throw a forward pass” and share a link with friends through Facebook. There's also a game app dubbed Goal Post Avenue.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...